Physician profile
Steven Mitchell
NPI 1710411509
$20,505.51
in general payments reported to CMS, 2019-2025
21 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $116 · 2021: $16K · 2022: $16.10 · 2023: $1,107 · 2024: $418 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,632 · Food and Beverage: $981 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,631.95 |
| Food and Beverage | $981.10 |
| Education | $210.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16,056.46 | 2021 | |
| Abbott Laboratories | $1,078.34 | 2023-2024 | Infinity |
| Boston Scientific Corporation | $972.38 | 2025 | Vercise, General - Dbs |
| Teva Pharmaceuticals USA, INC. | $346.83 | 2019-2024 | Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $229.70 | 2019 | |
| Biogen, INC. | $227.78 | 2019 | |
| Genzyme Corporation | $225.26 | 2019 | |
| Abbvie INC. | $216.60 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $153.98 | 2019 | |
| Eisai INC. | $133.52 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $125.00 | 2021 | |
| Amgen INC. | $120.80 | 2019 | |
| Neurocrine Biosciences, INC. | $120.43 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $116.26 | 2020 | |
| Kyowa Kirin, INC. | $112.45 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $100.85 | 2025 | |
| Alexion Pharmaceuticals, INC. | $82.17 | 2019 | |
| Pfizer INC. | $27.49 | 2024 | |
| Supernus Pharmaceuticals, INC. | $25.60 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.